Strs Ohio Invests $6.69 Million in Masimo Corporation $MASI

Key Points

• Strs Ohio has invested approximately $6.69 million in Masimo Corporation, acquiring over 40,000 shares in the first quarter, representing a 0.07% ownership stake in the company.
• Masimo reported quarterly earnings of $1.33 EPS, exceeding analyst expectations, with revenue increasing by 7.7% year-over-year to $370.9 million.
• Institutional investors and hedge funds hold a substantial 85.96% of Masimo's stock, reflecting strong interest among large financial entities.

Strs Ohio bought a new position in shares of Masimo Corporation (NASDAQ:MASI - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 40,135 shares of the medical equipment provider's stock, valued at approximately $6,686,000. Strs Ohio owned 0.07% of Masimo at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in MASI. GAMMA Investing LLC boosted its position in shares of Masimo by 58.4% during the first quarter. GAMMA Investing LLC now owns 738 shares of the medical equipment provider's stock valued at $123,000 after buying an additional 272 shares during the last quarter. NBC Securities Inc. bought a new stake in shares of Masimo during the 1st quarter valued at $61,000. Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in Masimo by 2.9% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,039 shares of the medical equipment provider's stock worth $673,000 after acquiring an additional 115 shares during the last quarter. UMB Bank n.a. boosted its holdings in shares of Masimo by 134.0% in the 1st quarter. UMB Bank n.a. now owns 447 shares of the medical equipment provider's stock worth $74,000 after purchasing an additional 256 shares in the last quarter. Finally, American Century Companies Inc. boosted its holdings in Masimo by 525.5% during the 1st quarter. American Century Companies Inc. now owns 79,176 shares of the medical equipment provider's stock valued at $13,191,000 after acquiring an additional 66,517 shares during the period. Institutional investors and hedge funds own 85.96% of the company's stock.

Masimo Trading Up 0.8%

MASI stock opened at $147.44 on Monday. The company's 50-day simple moving average is $152.26 and its 200-day simple moving average is $159.09. The company has a quick ratio of 1.61, a current ratio of 2.14 and a debt-to-equity ratio of 0.57. Masimo Corporation has a 52-week low of $111.03 and a 52-week high of $194.88. The firm has a market cap of $8.01 billion, a P/E ratio of -17.31 and a beta of 1.23.

Masimo (NASDAQ:MASI - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The medical equipment provider reported $1.33 earnings per share for the quarter, beating analysts' consensus estimates of $1.22 by $0.11. The firm had revenue of $370.90 million for the quarter, compared to analyst estimates of $368.65 million. Masimo had a negative net margin of 24.85% and a positive return on equity of 26.54%. Masimo's quarterly revenue was up 7.7% compared to the same quarter last year. During the same period last year, the company posted $0.86 EPS. As a group, equities analysts forecast that Masimo Corporation will post 4.1 EPS for the current fiscal year.

Insider Activity at Masimo

In other Masimo news, Director William R. Jellison purchased 3,000 shares of the company's stock in a transaction on Monday, August 11th. The stock was acquired at an average price of $145.98 per share, for a total transaction of $437,940.00. Following the completion of the purchase, the director directly owned 4,790 shares in the company, valued at approximately $699,244.20. The trade was a 167.60% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 9.70% of the stock is currently owned by company insiders.

Analyst Ratings Changes

MASI has been the subject of several research reports. Wall Street Zen lowered Masimo from a "buy" rating to a "hold" rating in a research report on Friday, May 30th. Piper Sandler lifted their target price on Masimo from $200.00 to $210.00 and gave the stock an "overweight" rating in a report on Wednesday, August 6th. BTIG Research reissued a "buy" rating and set a $198.00 price objective on shares of Masimo in a research note on Thursday. Finally, Zacks Research upgraded Masimo from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, September 3rd. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $194.60.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.

Want to see what other hedge funds are holding MASI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Masimo Corporation (NASDAQ:MASI - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.